Peginterferon Alfa-2A

證據等級: L5

預測適應症: 10 個

Peginterferon Alfa-2a: From Chronic Viral Hepatitis to Hepatitis B Virus Infection

One-Sentence Summary

Peginterferon Alfa-2a (DrugBank DB00008) is a pegylated interferon widely used in the treatment of chronic viral hepatitis. The TxGNN model predicts it may also be effective for Hepatitis B Virus Infection, with 50 clinical trials and 20 publications currently supporting this direction — including a landmark Phase III registration RCT.

Quick Overview

Item	Content
Original Indication	Data not available in the current evidence pack (no license records returned)
Predicted New Indication	Hepatitis B Virus Infection
TxGNN Prediction Score	99.94%
Evidence Level	L1
US Market Status	Not Marketed (per current dataset — no license records found)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacological information, Peginterferon Alfa-2a is a pegylated recombinant interferon alfa-2a — a cytokine with combined antiviral, immunomodulatory, and antiproliferative properties. It has been widely used as a foundational therapy for chronic hepatitis C, and mechanistically this broad antiviral/immune-stimulating activity may be applicable to hepatitis B virus infection.

Chronic hepatitis B and chronic hepatitis C are both hepatotropic viral infections that share overlapping treatment rationale: both benefit from interferon-induced upregulation of interferon-stimulated genes (ISGs), suppression of viral replication, and restoration of host antiviral immune responses. Unlike direct-acting antivirals that target virus-specific enzymes, interferon-based therapy acts on host immune pathways, which is why it has clinical utility across multiple hepatotropic viruses (HCV, HBV, and even HDV, as reflected in the evidence pool).

This mechanistic plausibility is further reinforced by the depth of the clinical evidence base: the predicted HBV indication is not a purely computational hypothesis but is corroborated by numerous completed Phase III/IV randomized trials and a landmark 2005 New England Journal of Medicine registration study, indicating that this repurposing signal reflects an already well-established clinical use pattern rather than a novel, untested hypothesis.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00114361	Phase 3	Completed	138	PARC Study — PEG-IFN + ribavirin vs. PEG-IFN monotherapy for 1 year in HBeAg-negative chronic HBV
NCT02604823	Phase 4	Completed	307	Efficacy/safety of Pegasys in naive, interferon- or lamivudine-pretreated HBeAg-positive CHB patients
NCT02598063	Phase 4	Completed	255	Peginterferon alfa-2a vs. adefovir dipivoxil in lamivudine-resistant HBeAg-positive CHB
NCT01938781	Phase 4	Completed	400	Entecavir ± peginterferon add-on for regression of HBV-induced liver fibrosis
NCT01667432	N/A (Observational)	Completed	141	On-treatment predictors of response to Pegasys in HBeAg-positive/negative CHB
NCT04412863	Phase 2	Completed	84	VIR-2218 alone or combined with peginterferon alfa-2a in chronic HBV infection
NCT02364336	Phase 2	Completed	14	NIH mechanistic study of peginterferon add-on after long-term nucleos(t)ide analogue therapy
NCT01471535	N/A (Observational)	Completed	20	HBsAg loss/seroconversion in inactive chronic HBV carriers treated with peginterferon alfa-2a
NCT02570191	Phase 4	Completed	60	Efficacy/safety of PEGASYS in HBeAg-negative chronic hepatitis B
NCT01237496	Phase 3	Completed	17	Immunology sub-study of ML18253 — HBV-specific T-cell responses under Pegasys therapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15987917	2005	RCT	The New England Journal of Medicine	Landmark Phase III trial comparing peginterferon alfa-2a ± lamivudine vs. lamivudine alone in HBeAg-positive chronic hepatitis B
18220290	2008	RCT	Hepatology	Analysis of 271-patient multinational Phase III registration trial; HBeAg/HBV DNA as predictors of response to peginterferon alfa-2a
19084016	2009	RCT	Gastroenterology	Peginterferon alfa-2a + ribavirin in patients dually infected with HBV and HCV
30549279	2019	RCT	Hepatology	Entecavir + peginterferon alfa-2a in HBeAg-positive immune-tolerant adults with chronic HBV
30318613	2019	RCT	Hepatology	Entecavir/peginterferon alfa-2a combination in children with immune-tolerant HBeAg-positive chronic HBV
33720089	2021	RCT	Journal of Pediatric Gastroenterology and Nutrition	Peginterferon alfa-2a + lamivudine or entecavir in children with immune-tolerant chronic hepatitis B
26700861	2015	RCT	Virology Journal	Double-blind randomized trial of long-term peginterferon alfa-2a effects in Japanese chronic HBV patients
29715359	2018	Review	JAMA	Comprehensive review of chronic hepatitis B infection, epidemiology and treatment landscape
21423260	2011	Review	Nature Reviews Gastroenterology & Hepatology	Review of hepatitis B therapy goals and treatment response monitoring
30865588	2019	Systematic Review / Meta-analysis	Antiviral Therapy	Individual participant data meta-analysis establishing peginterferon alfa-2a stopping rules in chronic HBV

US Market Information

No US marketing authorization (NDA) records are currently available in this dataset for Peginterferon Alfa-2a. total_licenses is reported as 0 and market status as “Not Marketed” in the source evidence pack; this should be independently verified against the official FDA/TFDA product registry before final decision-making.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The efficacy evidence for hepatitis B virus infection is strong (Evidence Level L1), supported by multiple completed Phase III/IV RCTs including a landmark 2005 NEJM registration trial. However, this evidence pack is missing TFDA/FDA-equivalent safety labelling (warnings, contraindications) and mechanism-of-action data, which is a Blocking-severity gap that prevents completion of the preliminary safety review (S1). No marketing authorization records are present in the current dataset either.

To proceed, the following is needed:

Official product label safety warnings and contraindications (TFDA/FDA source)
Confirmed mechanism of action (MOA) data from DrugBank
Verification of current market/license status and original approved indication text
Drug-drug interaction (DDI) data, currently returned as “not found”
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.